Walgreens Completes Acquisition of CuraScript Infusion Pharmacy, Inc.
Walgreen Co. (NYSE, NASDAQ: WAG), through its subsidiary Option Care Enterprises, Inc., has completed its acquisition of CuraScript Infusion Pharmacy, Inc., a wholly-owned subsidiary of Express Scripts, Inc. CuraScript Infusion Pharmacy, based in Louisville, Ky., is one of the nation’s largest providers of infusion services and for nearly 17 years has supported patients who require complex therapies including anti-viral, immune deficiency, inotropic, chemotherapy and pain management treatments. Walgreens acquired each of CuraScript Infusion Pharmacy’s 12 facilities located in Alabama, Indiana, Kentucky, Missouri, Ohio and Tennessee. Terms of the agreement were not disclosed.
Paul Mastrapa, president of Walgreens-OptionCare, said, “This acquisition further expands our national coverage in home infusion services. We now operate more than 100 home infusion locations in 35 states. CuraScript Infusion Pharmacy is highly regarded in the industry for its clinical expertise and commitment to exceptional patient care. We welcome this addition to our infusion pharmacy network and look forward to reaching even more patients with this combined high level of personalized therapy and support.”
Express Scripts, Inc. is retaining ownership of CuraScript Specialty Pharmacy and CuraScript Specialty Distribution.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.